May 4, 2023 News by Marisa Wexler, MS High NfL levels seen in children near times of disease activity: Study Blood levels of the nerve damage marker NfL seem to spike to very high levels around times of disease activity in children with multiple sclerosis (MS), a new study reports. The findings support using NfL as a biomarker of disease activity, in the form of relapses or lesions, in…
December 20, 2022 News by Lindsey Shapiro, PhD Review Study Highlights Potential of NfL as MS Prognosis Biomarker Levels of neurofilament light chain (NfL), a biomarker of nerve cell damage, may help predict multiple sclerosis (MS) prognosis and response to treatment with Gilenya (fingolimod), according to a review of five randomized clinical trials. Most of the evaluations in the review study were qualitative, however, meaning trial…
July 25, 2022 News by Vanda Pinto, PhD ‘Brain Healthy Lifestyle’ May Help Prevent Disability Progression Leading a healthy cognitive and physically active lifestyle, including having a normal body weight and well-controlled blood pressure, may increase brain reserve ā the brain’s ability to adapt after damage ā and delay disability progression in multiple sclerosis (MS), according to a new study. The study, āLifestyle factors…
July 20, 2022 News by Vanda Pinto, PhD Accessible NfL Blood Test Developed for Neurodegenerative Conditions Labcorp has launched a widely accessible test that measures the levels of neurofilament light chain (NfL), a biomarker of nerve damage, to screen for signs of neurodegenerative diseases such as multiple sclerosis (MS). The test is performed on a standard blood sample taken at a hospital, at the…
October 28, 2019 Columns by Ed Tobias MS News that Caught My Eye Last Week: Cognitive Impairment, Genetic Variant Risk Factor, Protein Biomarkers, Gilenya Study Higher Intellectual Ability, Early-life Physical Activity May Protect Against Cognitive Impairment in MS, Study Suggests The finding that physical activity provides a protective effect for cognitive abilities makes sense to me. I recently listened to a webinar discussing brain atrophy, which has a direct relationship with cognitive impairment, and…
September 19, 2019 News by Ana Pena PhD #ECTRIMS2019 – Ocrevus Living Up to ‘Game-changing’ Moniker, Genentech’s Hideki Garren Says in Interview Two years after the approval of Ocrevus (ocrelizumab), the latest data continue to support the benefits of the so-called “game-changing” therapy in multiple sclerosis (MS), while new insights highlight its neuronal protective effects and safety. Multiple Sclerosis News Today had the opportunity to speak with Hideki Garren,…
May 14, 2019 News by Jose Marques Lopes, PhD #AANAM ā Ocrevus Lowers Markers of Inflammation, Damage in Relapsing MS Patients, Phase 3 Trial Shows Treatment with Ocrevus (ocrelizumab) decreases the levels of neurofilament light chain (NfL) and immune B-cells in the serum and central nervous system of patients with relapsing multiple sclerosis (MS), according to results from a Phase 3 trial. The research, āOcrelizumab treatment reduced levels of neurofilament light chain and…